Form 4: Amicus Therapeutics CEO Sells Shares Under 10b5-1 Plan

Amicus Therapeutics President and CEO, Bradley L. Campbell, sold 22,500 shares of common stock for approximately $14.35 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Bradley L. Campbell, President and CEO, and a Director of Amicus Therapeutics, Inc. (FOLD), disposed of 22,500 shares of common stock.
• The shares were sold on March 2, 2026, at a weighted average price of $14.3484 per share, with individual transaction prices ranging from $14.34 to $14.37.
• Following this transaction, Campbell directly beneficially owns 998,680 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Campbell on September 12, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale reduces executive ownership, the execution under a pre-arranged 10b5-1 plan suggests a planned financial management decision rather than a reaction to new negative information.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and orderly disposition of shares rather than an opportunistic sale based on immediate market conditions or non-public information.

Negatives

• An insider sale by a high-ranking executive, even under a 10b5-1 plan, reduces the executive's direct ownership stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider sales, particularly by top executives, are closely watched by investors for signals about management's confidence in the company's future prospects. While a sale under a Rule 10b5-1 plan typically mitigates concerns about opportunistic timing, it still represents a reduction in direct ownership by a key leader.

Comparison to Industry Standards

• Insider sales under Rule 10b5-1 plans are a common practice among executives in publicly traded companies, including those in the biotechnology and pharmaceutical sectors, to manage personal finances while avoiding accusations of trading on material non-public information. This transaction aligns with standard practices for executive stock dispositions.

Stakeholder Impact

• Shareholders may interpret the sale as a slight reduction in management's direct financial alignment, though the 10b5-1 plan context often softens this perception.
• Employees, customers, suppliers, and creditors are unlikely to be directly impacted by this specific insider trading report.

Key Dates

Recommendation

The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of a significant change in the company's fundamental outlook or a signal for immediate investment action. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide sufficient new information to warrant a change in investment thesis.

Keywords

Amicus Therapeutics, FOLD, Insider Trading, Form 4, Bradley L. Campbell, CEO, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals